Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17791885 | 0.71 | GPR35 (0.47) | HSD17B3ANTXR2GPR55GPR35ADORA3 | |
| SCHEMBL1735944 | 0.70 | KDM4E (0.45) | ADORA2AMAOA | |
| SCHEMBL17696461 | 0.69 | HSD17B3 (0.42) | HSD17B3ANTXR2GPR55GPR35ADORA3 | |
| SCHEMBL20097975 | 0.68 | HSD17B3 (0.41) | HSD17B3ANTXR2GPR55GPR35ADORA3 | |
| SCHEMBL11392013 | 0.67 | MAPK1 (0.57) | HSD17B3ANTXR2GPR55GPR35ADORA3 | |
| SCHEMBL8171798 | 0.66 | GPR35 (0.58) | HSD17B3ANTXR2GPR35MAOA | |
| Hydrochloric Acid SCHEMBL2291019 | 0.64 | HPGD (0.58) | HSD17B3GPR35MAOA | |
| SCHEMBL19519553 | 0.64 | HSD17B3 (0.49) | HSD17B3ANTXR2GPR55GPR35ADORA3 | |
| SCHEMBL15842923 | 0.62 | HSD17B3 (0.60) | HSD17B3ADORA3 | |
| SCHEMBL29270317 | 0.62 | ADORA1 (0.57) | HSD17B3ANTXR2GPR35ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481709-B2 | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism | OBE THERAPY BIOTECHNOLOGY (FR) | 2016-11-01 | — | — | US | disclosed |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, FABP4 | HSD17B3 878/4885ANTXR2 129/4885GPR55 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.